Launched in 2003, the Kidney Cancer Journal serves as the most comprehensive, peer-reviewed resource of information for physicians on the diagnosis and treatment of renal cell carcinoma and all of its tumor types. Published quarterly and guided by a Medical Advisory Board and an Editorial Advisory Board of leading investigators and thought leaders involved in pivotal clinical trials, the Kidney Cancer Journal and its International Edition focus on the impact of translational research in oncology and urology.
Reviewing new data in the peer-reviewed medical literature, presenting case histories, and evaluating the merits of bench research, the journal offers an in-depth analysis of trends affecting patient care. The Kidney Cancer Journal is the official journal of the Kidney Cancer Association and provides Continuing Medical Education credit in association with City of Hope National Medical Center, Duarte, California. Through its review of manuscript submissions by the Medical Advisory Board and Editorial Advisory Board, the journal seeks to provide the most reliable, authoritative, and scientifically rigorous information available to physicians involved in the management of renal cancer. This audience includes medical oncologists, hematologist-oncologists, and urologists.
With the advisory boards serving as a touchstone for the latest information on new drug development, the journal also alerts its readers to the relevance of ongoing clinical trials, the availability of trial enrollment, the protocols of such research, and the progress made toward the approval of new agents undergoing study. As part of its mission to inform its readership, the journal also reports on data presented at major medical meetings, including the Scientific Sessions of the American Society of Clinical Oncology, the American Urological Association and the International Symposia of the Kidney Cancer Association.